Abstract
Antipsychotic drugs have been the drugs of choice for the treatment of schizophrenia ever since the introduction of chlorpromazine in the early 1950s of the last century. Since then, about 60 different antipsychotics have been introduced. Although pharmacologically these drugs show large differences, in terms of potency, duration of action and selectivity, all antipsychotics appear to reduce the positive symptoms of schizophrenia, while having little or no effect on the negative symptoms or the cognitive deficits. The only apparent exception is clozapine, which is also effective in therapy-resistant patients. On the other hand, antipsychotics induce significant side effects as well, including neurological, behavioural and metabolic side effects. In the present paper, we will discuss the preclinical pharmacology of the current antipsychotic drugs focussing both on the therapeutic and on side effects of these drugs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aggernaes B, Glenthoj BY, Ebdrup BH et al (2010) Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months’ treatment with quetiapine. Int J Neuropsychopharmacol 13:1383–1395
Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321–329
Arnt J (1983) Neuroleptic inhibition of 6,7-ADTN-induced hyperactivity after injections into the nucleus accumbens. Specificity and comparison with other models. Eur J Pharmacol 90:47–55
Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur J Pharmacol 283:55–62
Arnt J (2000) Screening models for antipsychotic drugs. In: Ellenbroek BA, Cools AR (eds) Atypical antipsychotics, edn. Birkhäuser Verlag, Basel, pp 99–119
Baptista T, LaCruz A, Paez X et al (2002a) The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? Eur J Pharmacol 447:91–98
Baptista T, LaCruz A, De Mendoza D et al (2002b) Body weight gain after administration of antipsychotic drugs. Pharmacopsychiatry 35:36
Braff D, Stone C, Callaway E et al (1978) Prestimulus effects of human startle reflex in normals and schizophrenics. Psychophysiology 15:339–343
Braff DL (2015) The importance of endophenotypes in schizophrenia research. Schizophr Res 163:1–8
Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181–188
Brutcher RE, Nader MA (2015) Effects of quetiapine treatment on cocaine self-administration and behavioral indices of sleep in adult rhesus monkeys. Psychopharmacology 232:411–420
Carlsson A, Lindqvist M (1963) Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramin and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144
Cha HJ, Lee HA, Ahn JI et al (2013) Dependence potential of quetiapine: behavioral pharmacology in rodents. Biomol Ther (Seoul) 21:307–312
De Fazio P, Gaetano R, Caroleo M et al (2015) Rare and very rare adverse effects of clozapine. Neuropsychiatric Dis Treat 11:1995–2003
Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278
Drago F, Contarino A, Marino R et al (1997) Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats. Pharmacol Res 35:17–25
During S, Glenthoj BY, Andersen GS et al (2014) Effects of dopamine d2/d3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients. Neuropsychopharmacology 39:3000–3008
Ellenbroek B, Cools AR (1988) The Paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci 42:1205–1213
Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57:1–78
Ellenbroek BA (2012) Psychopharmacological treatment of schizophrenia: what do we have and what could we get? Neuropharmacology 62:1371–1380
Ellenbroek BA (2015) Schizophrenia: animal models. In: Stolerman IP, Price LH (eds) Encyclopedia of psychopharmacology, edn, vol 2. Springer, Heidelberg, pp 1501–1508
Ellenbroek BA, Ghiabi B (2015) Do histamine receptor 3 antagonists have a place in the therapy for schizophrenia? Curr Pharm Des 21:3760–3770
Ellenbroek BA, Cesura AM (2015) Antipsychotics and the dopamine—serotonin connection. In: Celanire S, Poli S (eds) Topics in medicinal chemistry, vol 13. Springer, Heidelberg, pp 1–50
Ellenbroek BA, Artz MT, Cools AR (1991) The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196:103–108
Ellenbroek BA, Prinssen EP, Cools AR (1994) The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 6:1–8
Ellenbroek BA, Lubbers LJ, Cools AR (1996) Activity of “seroquel” (ICI 204,636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 15:406–416
Ellenbroek BA, Peeters BW, Honig WM et al (1987) The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology Berl 93:343–348
Ersland KM, Skrede S, Rost TH et al (2015) Antipsychotic-induced metabolic effects in the female rat: direct comparison between long-acting injections of risperidone and olanzapine. J Psychopharmacol 29:1280–1289
Farde L, Wiesel FA, Halldin C et al (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76
Fusar-Poli P, Papanastasiou E, Stahl D et al (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41:892–899
Geyer MA, Krebs-Thomson K, Braff DL et al (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenic patients: a decade in review. Psychopharmacology 156:117–154
Goldstein JM, Litwin LC, Sutton EB et al (1989) Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 249:673–680
Goudie AJ, Cooper GD, Halford JCG (2005) Antipsychotic-induced weight gain. Diabetes Obes Metab 7:478–487
Graham F (1975) The more or less startling effects of weak prepulses. Psychophysiology 12:238–248
Haase HJ (1954) About prevalence and interpretation of the psychomotor parkinson syndrome in megaphen or largactil treatment duration. Nervenarzt 25:486–492
Haase HJ, Floru L, Knaack M (1974) Clinical importance of neuroleptic threshold and its fine motor determination by handwriting test. J Int Med Res 2:321–330
Hartfield AW, Moore NA, Clifton PG (2003) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology 167:115–122
Ishibashi T, Horisawa T, Tokuda K et al (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171–181
Janssen PAJ, Niemegeers CJE, Schellekens KHL (1965) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I: neuroleptic activity spectra for rats. Arzneimittelforschung 15:104–117
Janssen PAJ, Niemegeers CJE, Schellekens KHL (1966) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part III: The subcutaneous and oral activity in rats and dogs of 56 neuroleptic drugs in the jumping box test. Arzneimittelforschung 16:339–346
Janssen PAJ, Niemegeers CJE, Schellekens KHL et al (1967) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part IV: An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-induced “chewing” and “agitation” in rats. Arzneimittelforschung 17:841–854
Just MJ (2015) The influence of atypical antipsychotic drugs on sexual function. Neuropsychiatric Dis Treat 11:1655–1661
Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097
Kegeles LS, Abi-Dargham A, Frankle WG et al (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231–239
Kelley BM, Porter JH (1997) The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707–719
Klein-Schwartz W, Schwartz EK, Anderson BD (2014) Evaluation of quetiapine abuse and misuse reported to poison centers. J Addict Med 8:195–198
La Torre A, Conca A, Duffy D et al (2013) Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 46:201–208
Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962
Leysen JE (2000) Receptor profile of antipsychotics. In: Ellenbroek BA, Cools AR (eds) Atypical antipsychotics. Birkhäuser Verlag, Basel, pp 57–81
Mackeprang T, Kristiansen KT, Glenthoj BY (2002) Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry 52:863–873
Madras BK (2013) History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci 22:62–78
Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacol Berl 94:507–514
Matthysse S (1986) Animal models in psychiatric research. Prog Brain Res 65:259–270
Meincke U, Morth D, Voss T et al (2004) Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis—A longitudinal study. Eur Arch Psychiatry Clin Neurosci 254:415–421
Meltzer HY, Matsubara S, Lee JC (1989) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390–392
Moncrieff J (2013) Magic bullets for mental disorders: the emergence of the concept of an “antipsychotic” drug. J Hist Neurosci 22:30–46
Montebello ME, Brett J (2016) Misuse and associated harms of quetiapine and other atypical antipsychotics. Curr Topics Behav Neurosci. doi:10.1007/7854_2015_424
Nielsen EB (1988) Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 94:115–118
Niemegeers CJ, Janssen PA (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24:2201–2216
Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97–103
Ogren SO, Hall H, Kohler C et al (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287–294
Ogren SO, Hall H, Kohler C et al (1984) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102:459–474
Porter JH, Prus AJ (2009) Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies. Psychopharmacology 203:279–294
Pouzet B, Mow T, Kreilgaard M et al (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133–140
Quednow BB, Wagner M, Westheide J et al (2006) Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biol Psychiatry 59:536–545
Snoeren E, Chan J, Bovens A et al (2010) Serotonin transporter null mutation and sexual behavior in female rats: 5-HT1A receptor desensitization. J Sex Med 7:2424–2434
Snoeren EMS, Veening JG, Olivier B et al (2014) Serotonin 1A receptors and sexual behavior in female rats: a review. Pharmacol Biochem Behav 121:43–52
Snyder SH, Greenberg D, Yamamura J (1974) Anti-schizophrenic drugsand brain cholinergic receptors. Arch Gen Psychiatry 31:58–61
Steck H (1954) Le syndrome extra-pyramidal et di-encephalique au cours des traitments au Largactil et au Serpasil. Ann Med Psychol 112:737–743
Stewart J (1962) Differential responses based on the physiological consequences of pharmacological agents. Psychopharmacologia 3:132–138
Thomas KV, Handley SL (1978) Modulation of dexamphetamine-induced compulsive gnawing—including the possible involvement of presynaptic alpha-adrenoreceptors. Psychopharmacology 56:61–67
van der Zwaal EM, Janhunen SK, la Fleur SE et al (2014) Modelling olanzapine-induced weight gain in rats. Int J Neuropsychopharmacol 17:169–186
van Rossum J (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492–494
Wadenberg MG, Hicks PB (1999) The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851–862
Zarate JM, Boksa P, Baptista T et al (2004) Effects of clozapine on behavioral and metabolic traits relevant for schizophrenia in two mouse strains. Psychopharmacology 171:162–172
Zhang XR, Zhang ZJ, Jenkins TA et al (2011) The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat. J Sex Med 8:3345–3353
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Sánchez, J.P.B., Ellenbroek, B.A. (2016). Preclinical Effects of Antipsychotic Drugs. In: Nielsen, S., Bruno, R., Schenk, S. (eds) Non-medical and illicit use of psychoactive drugs. Current Topics in Behavioral Neurosciences, vol 34. Springer, Cham. https://doi.org/10.1007/7854_2016_447
Download citation
DOI: https://doi.org/10.1007/7854_2016_447
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-60014-7
Online ISBN: 978-3-319-60016-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)